The text starts here.

News Release

Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.

1996 Release

December 19, 1996 Eisai and Astra Settle Patent Dispute Regarding a Proton Pump Inhibitor
December 12, 1996 Distribution of "ProHance Injection", Non-ionic MRI Diagnostic Agent, to Be Unified through Eisai
December 12, 1996 Eisai Licenses Antifungal Triazole to Bristol-Myers Squibb
November 26, 1996 Eisai Contracts for Land Use for the Establishment of a Pharmaceutical Production Site in Suzhou, China
November 25, 1996
(EST)
Eisai Receives FDA Marketing Clearance for ARICEPT(TM) (donepezil hydrochloride), A New Treatment for Alzheimer's Disease - Improves Cognition and Patient Function; is Well Tolerated -
October 11, 1996 Eisai Submits a Marketing Authorisation Application (MAA) for ARICEPT(TM)(donepezil hydrochloride) - A New Drug Studied in the Treatment of Alzheimer's Disease in the UK-
September 25, 1996 Eisai Co., Ltd. Confirms Receipt of FDA Approvable Letter
July 4, 1996 Eisai Starts Construction of 4th Production (Packaging) Facility at Kawashima Production Facilities
June 6, 1996 Eisai Purchases Land for Production of Synthetic Vitamin E in the U.S.
May 1, 1996
(EST)
Eisai Pharmatechnology, Inc. Breaks Ground on $40 Million Facility at Research Triangle Park
April 22, 1996 Nippon Glaxo and Eisai End Joint Development and Marketing Agreement for SN-308
April 9, 1996 Eisai Establishes Elmed Eisai Co., Ltd. Selling "Value Generics"
March 29, 1996
(EST)
Eisai Submits NDA for ARICEPT(TM) (donepezil hydrochloride), A New Drug Studied in the Treatment of Alzheimer's Disease
March 26, 1996 Eisai Announces Positive Results of U.S. Phase III Clinical Trials for Drug Studied in the Treatment of Alzheimer's Disease
March 1, 1996 AHP and Eisai End their Joint Venture Partnership

Back to Top